Drug maker agrees to stop selling Opana ER because of misuse | Behavioral Healthcare Executive Skip to content Skip to navigation

Drug maker agrees to stop selling Opana ER because of misuse

July 6, 2017
by Julie Miller, Editor in Chief
| Reprints

Endo Pharmaceuticals on Thursday agreed to remove its long-acting Opana ER (oxymorphone hydrochloride) pain drug from the market, about a month after FDA Commissioner Scott Gottlieb, MD, requested that the company stop selling the product because of the growing incidents of manipulation and misuse.

The controversy with Opana ER dates back to March, when an FDA advisory committee decided by an 18-to-8 vote that the benefits of the abuse-deterrent formulation of the product no longer outweighed its risks. Postmarket studies show individuals are still able to manipulate the tablets and inject the substance. Injection of reformulated Opana ER also has been associated with a serious outbreak of HIV and hepatitis C, according to FDA.

An outbreak of HIV in Indiana in 2015 was, in part, tied to misuse of the drug.

According to Endo, net sales of Opana ER were $158.9 million in 2016, and the company maintains that the long-acting pain drug has positive benefits and is safe when used as intended. Had officials not agreed to pull the drug, FDA would have removed it from the market anyway by withdrawing approval.

Opana ER was first approved in 2006. Six years later, Endo replaced the original formulation of with an updated abuse-deterrent formulation intended to make the tablets resistant to physical and chemical manipulation for the purpose of misuse by snorting or injecting.

Separately, Gottlieb also scheduled a public meeting on July 10-11 to examine all opioid medications with abuse-deterrent properties.